“Can stem cells cause cancer?” is one of the most important safety questions patients ask before regenerative therapy.

Current human clinical evidence does not show that properly manufactured mesenchymal stem cell (MSC) therapy causes cancer. However, active malignancy is typically considered a contraindication, and appropriate patient screening is essential.

Why This Question Exists

The concern is biologically understandable. Stem cells have the capacity for self-renewal and proliferation. Cancer cells also proliferate uncontrollably. The surface similarity raises a logical question: could stem cells transform into tumors or stimulate cancer growth?

The answer depends on:

• The type of stem cell
• Manufacturing standards
• Passage number and expansion control
• Patient selection

This discussion focuses specifically on mesenchymal stromal/stem cells (MSCs), including umbilical cord–derived MSCs (UC-MSCs), which are commonly used in regenerative medicine.

Not All Stem Cells Carry the Same Risk

Tumor formation concerns largely originate from pluripotent stem cells such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). These cells can form teratomas in animal models if injected without controlled differentiation.

Mesenchymal stem cells are different. MSCs are multipotent, not pluripotent. They do not naturally form teratomas in human clinical settings. Their therapeutic mechanism is primarily immunomodulatory and paracrine, meaning they influence inflammatory signaling and tissue microenvironments rather than directly replacing tissue through aggressive proliferation.

A review discussing MSC tumorigenicity notes that while laboratory concerns exist, clinical-grade MSCs have not demonstrated teratoma formation in human trials:

What Large Clinical Safety Data Show

MSCs have been administered in thousands of patients worldwide across inflammatory, orthopedic, and immune-mediated conditions.

A systematic review evaluating MSC safety across multiple clinical trials found no association between MSC administration and increased tumor formation:

A subsequent long-term follow-up analysis similarly did not demonstrate increased malignancy risk attributable to MSC therapy:

Importantly, these analyses include systemic (intravenous) administration, which exposes the entire body to cells. If MSCs carried a strong intrinsic oncogenic risk, it would likely have emerged in these datasets.

To date, controlled human clinical evidence does not show a reproducible signal of MSC-induced cancer.

Where Theoretical Concerns Come From

Although clinical evidence is reassuring, scientific caution remains appropriate. The theoretical discussion usually involves three areas.

1. Could MSCs Transform Into Cancer?

In laboratory settings, prolonged cell expansion beyond normal limits can lead to replicative senescence and genetic instability. This is why regulated manufacturing limits passage number.

Replicative senescence and passage-dependent changes in MSCs have been well characterized. Clinical-grade MSC products are typically used at early-to-mid passages (commonly P3–P5) and undergo quality testing for:

• Sterility
• Viability
• Surface marker identity (CD73, CD90, CD105)
• Morphology

There is no consistent evidence of spontaneous malignant transformation of properly manufactured MSCs in humans.

2. Could MSCs Stimulate an Existing Cancer?

MSCs release signaling molecules such as VEGF, TGF-β, and HGF. In preclinical models, MSCs have demonstrated both tumor-promoting and tumor-inhibiting behavior depending on cancer type and microenvironment.

This does not mean MSCs cause cancer. It means that in patients with active malignancy, altering the inflammatory or immune environment could theoretically influence tumor biology. For this reason, active cancer is generally considered a contraindication in responsible clinical practice.

3. Reports From Unregulated Settings

Isolated adverse case reports associated with stem cell therapy have typically involved:

• Non-GMP laboratories
• Unknown cell sources
• No passage control
• No sterility documentation
• Lack of physician oversight

These cases reflect regulatory and manufacturing failures rather than evidence that clinical-grade MSCs are inherently carcinogenic.

Regulatory Status vs. Cancer Risk

Mesenchymal stem cell therapies for orthopedic or anti-aging indications are not broadly FDA-approved as standardized pharmaceutical products. However, absence of FDA approval does not imply evidence of carcinogenicity.

It reflects:

• Ongoing clinical development
• Lack of standardized dosing frameworks
• Evolving regulatory pathways

Regulatory classification should not be confused with demonstrated cancer risk

Oncology Research Perspective

MSCs are being investigated as targeted delivery vehicles for anti-cancer therapies because of their ability to home toward inflammatory or tumor environments. The existence of such trials underscores that MSCs are not broadly recognized as intrinsically oncogenic in humans.

What We Know vs. What We Do Not Know

What current evidence supports:

• No consistent signal of tumor formation in human MSC clinical trials
• No demonstrated increase in malignancy rates in systematic safety analyses
• Feasibility and general tolerability under controlled manufacturing conditions

What remains under study:

• Very long-term (>10–15 year) surveillance data
• Effects in patients with prior cancer history
• Standardization of manufacturing variables globally

Medicine operates on evolving evidence. Current data suggest low observed tumor risk in screened patients receiving regulated MSC therapy, but continued monitoring remains appropriate.

Based on current peer-reviewed human clinical evidence, properly manufactured mesenchymal stem cell therapy has not been shown to cause cancer. Theoretical concerns exist in laboratory models and in the context of active malignancy. This is why screening, regulated manufacturing, and appropriate patient selection remain essential components of safe clinical practice.

Frequently Asked Questions

• Can umbilical cord stem cells cause cancer?

Current clinical evidence does not demonstrate that properly manufactured UC-MSC therapy causes cancer. Active malignancy is typically excluded before treatment.

• Do stem cells increase tumor markers?

There is no consistent clinical evidence that MSC therapy increases tumor markers in patients without underlying malignancy. Screening is often performed before treatment as a precaution.

• Can stem cells reactivate dormant cancer?

There is no conclusive human clinical evidence showing MSC therapy reactivates dormant cancer. However, patients with active or recent malignancy are usually evaluated cautiously or excluded.

About EDNA Wellness

EDNA Wellness is a private Stem Cell Clinic and Regenerative Medicine Center in Bangkok, Thailand, specializing in Umbilical cord–derived Mesenchymal Stem Cells (UC-MSCs) for knee osteoarthritis and joint pain, stroke and other neuro-related conditions, and stem cell IV infusions for longevity and healthy aging. All treatments are doctor-designed and performed in a sterile clinical setting

For more information or to book a consultation:

LINE: @ednawellness

WhatsApp: +66 (0) 64 505 5599

Website: www.ednawellness.com

References

• Wagner W et al. Replicative senescence of mesenchymal stem cells.
  https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0002213
• Lalu MM et al. Safety of Cell Therapy with Mesenchymal Stromal Cells https://pmc.ncbi.nlm.nih.gov/articles/PMC3485008/
• Thompson M et al. Long-term safety of MSC therapy https://www.sciencedirect.com/science/article/pii/S2589537019302585
• Dandan Wang et al. A Long-Term Follow-Up Study of Allogeneic Mesenchymal Stem/Stromal https://pmc.ncbi.nlm.nih.gov/articles/PMC5918528